Regresa al Registro Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorray coquard, isabelle
dc.contributor.authorLorusso, Domenica
dc.contributor.authorOAKNIN, ANA
dc.contributor.authorCibula, David
dc.contributor.authorVergote, Ignace
dc.contributor.authorVan Gorp, Toon
dc.date.accessioned2023-05-12T07:29:24Z
dc.date.available2023-05-12T07:29:24Z
dc.date.issued2023
dc.identifier.citationVergote I, Ray-Coquard I, Lorusso D, Oaknin A, Cibula D, Gorp T Van. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline? Expert Opin Investig Drugs. 2023;32(3):201–11.
dc.identifier.issn1744-7658
dc.identifier.urihttps://hdl.handle.net/11351/9517
dc.descriptionCáncer cervical recurrente; Terapia de combinación; Inmunoterapia
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofseriesExpert Opinion on Investigational Drugs;32(3)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectColl uterí - Càncer - Tractament
dc.subjectFarmàcia - Investigació
dc.subjectImmunoglobulines
dc.subject.meshUterine Cervical Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshDrugs, Investigational
dc.subject.meshImmunoconjugates
dc.titleInvestigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1080/13543784.2023.2179483
dc.subject.decsneoplasias del cuello uterino
dc.subject.decs/farmacoterapia
dc.subject.decsfármacos en investigación
dc.subject.decsinmunoconjugados
dc.relation.publishversionhttps://doi.org/10.1080/13543784.2023.2179483
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Vergote I, Van Gorp T] Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium, European Union. [Ray-Coquard I] Medical Oncology Department, Centre Léon Bérard and University Claude Bernard Lyon 1, GINECO, Lyon, France. [Lorusso D] Gynecologic Oncology Unit, Catholic University of Sacred Heart and Fondazione Policlinico Gemelli IRCCS, Rome, Italy. [Oaknin A] Gynecologic Cancer Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Cibula D] Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Central and Eastern European Gynecologic Oncology Group (CEEGOG), Prague, Czech Republic
dc.identifier.pmid36803278
dc.identifier.wos000945513700001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Regresa al Registro Simple